Secretome Therapeutics, Inc. — Form D
Secretome Therapeutics, Inc. of DALLAS, TX, a company, filed a Form D exempt-offering notice with the SEC on 2023-02-02. The offering totals $10.9M, of which $6.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-02-02
- Form: D
- Accession: 0001961833-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.9M
- Amount sold: $6.9M
- Remaining: $4.0M
- Minimum investment: $1
- Investors: 48
- Date of first sale: 2022-11-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-472444
Issuer
- Name: Secretome Therapeutics, Inc.
- CIK: 0001961833
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 3060 PEGASUS PARK DR, DALLAS, TX, 75247
- Phone: 646.526.9628
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| VINEET JINDAL | Director | DALLAS, TX |
| SUNJAY KAUSHAL | Director | DALLAS, TX |
| William Niland | Director | Baltimore, MD |
| HENRIK RASMUSSEN | Director | DALLAS, TX |
| ANGELA SHEN | Director | DALLAS, TX |
| VINEET JINDAL | Executive Officer | DALLAS, TX |
More